FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C.	20549

STATEMENT	OF (CHANGES	IN BE	NEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0								
Estimated average burden								
hours per response	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* San Martin Javier				2. Issuer Name and Ticker or Trading Symbol Athira Pharma, Inc. [ATHA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify						
(Last)	(F IIRA PHAI	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 04/15/2024)	below)		below) OFFICER	, I		
18706 N	ORTH CRE	EEK PARKWAY	, SUITE 104	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)				Line	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	LL W	/A	98011)	_	ed by More		rting Person One Report	ing
(City)	(S	tate)	(Zip)	F	Rule 10b5-1(c) Transaction Indication											
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									satisfy						
		Та	ble I - Non-l	Derivati	ve Se	curitie	s Ac	quired, D	isposed o	of, or Be	neficially	Owned				
Date			?. Transactio Date Month/Day/	Execution Date		Code (Instr.			5. Amoun Securities Beneficia Owned Fo Reported	s Form Illy (D) o ollowing (I) (In		: Direct II Indirect E str. 4) ('. Nature of ndirect Beneficial Dwnership Instr. 4)			
						Code	Amount	(A) o (D)	r Price	Transaction (Instr. 3 a	action(s)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		e, Transa Code (5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	s Ily	Ownership of Form: Bo Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	Jil(9)		
Stock Option (Right to Buy)	\$2.06	04/15/2024		A		400,000		(1)	04/14/2034	Common Stock	400,000	\$0	400,00	0	D	

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option will vest on the one (1) year anniversary of the date of grant, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2024 Inducement Equity Incentive Plan) through the applicable vesting dates.

/s/ Mark Worthington,

Attorney-in-Fact for Javier San 04/16/2024

Martin

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.